

Singular Health Group Ltd: SHG

ASX Announcement

17th April 2023

Resignation of CEO and Managing Director and Strategic Review

17 April 2023 – Singular Health Group Ltd (ASX: SHG) (“Singular Health”, or “the Company”) wishes to announce that Singular Health’s Chief Executive Officer and Managing Director, Mr Thomas Hanly, has tendered his resignation effective as of 14th April 2023.

Mr Denning Chong, a co-founder, and Non-Executive Director of Singular Health, has been appointed as Interim Chief Executive Officer and Managing Director, on the material terms attached to this announcement, and shall work with the Board and senior management during this transition process until a new Chief Executive Officer is appointed.

Mr Chong will immediately commence a strategic review of the Company’s activities, with a focus on streamlining efficiencies, reducing expenditure, and prioritising the finalisation and execution of the numerous global commercial opportunities currently in progress by the Company.

Having joined Singular Health as the Managing Director and Chief Executive Officer in 2019, Mr Hanly has played a pivotal role in the initial foundation building of the Company, the product roadmap and the Company’s various commercial milestones such as the highly successful IPO in February 2021, and more recently the FDA regulatory clearance in October 2022, the Global3D acquisition completed in January 2023, the Sony collaboration and the ISO13485 certification in March 2023. Mr Hanly shall remain engaged by the Company as a consultant on certain strategic matters and R&D activities.

Howard Digby, Singular Health’s Chairman, said:

“Mr Thomas Hanly has been an abiding figure in Singular Health’s journey, providing valuable input, leadership, and guidance to our staff. Having worked with Tom over the past few years, the Board can attest to Tom’s passion for Singular Health. The Board wishes to thank Tom for his role in the progress of the Company, his commitment to the role, and his part in achieving many significant milestones during his tenure. We wish him all the best in his future endeavours.

“We move forward under the stewardship of co-founder, Mr Denning Chong as Interim CEO. As co-founder and Director since inception, Denning is very experienced and well placed to provide the inspiration, support, and guidance needed for this phase.”

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary + 61 8 9322 7600

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health’s 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices.

To learn more, please visit: www.singular.health

Material Terms for Interim Chief Executive Officer and Managing Director Appointment

Role Title	Interim Chief Executive Officer & Managing Director
Remuneration	Mr Denning Chong’s remuneration shall remain at \$80,000 p.a. and shall be accrued to be paid in future in cash or equity.
Term	Ongoing with no fixed term
Termination	The Board may terminate Mr Denning Chong’s role as Chief Executive Officer and/or Managing Director on 1 months’ notice.